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Abstract Mechanical allodynia (other pain) is a painful sen-
sation caused by innocuous stimuli like light touch. Unlike
inflammatory hyperalgesia that has a protective role, allodynia
has no obvious biological utility. Allodynia is associated with
nerve damage in conditions such as diabetes, and is likely to
become an increasing clinical problem. Unfortunately, the
mechanistic basis of this enhanced sensitivity is incompletely
understood. In this review, we describe evidence for the
involvement of candidate mechanosensitive channels such as
Piezo2 and their role in allodynia, as well as the peripheral and
central nervous system mechanisms that have also been im-
plicated in this form of pain. Specific treatments that block
allodynia could be very useful if the cell and molecular basis
of the condition could be determined. There are many poten-
tial mechanisms underlying this condition ranging from alter-
ations in mechanotransduction and sensory neuron excitabil-
ity to the actions of inflammatorymediators and wiring chang-
es in the CNS. As with other pain conditions, it is likely that
the range of redundant mechanisms that cause allodynia will
make therapeutic intervention problematic.
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Summary
Mechanical allodynia (‘other pain’) is a painful sensation
caused by innocuous stimuli like light touch. Unlike inflam-
matory hyperalgesia that has a protective role, allodynia has
no obvious biological utility. Allodynia is associated with
nerve damage in conditions such as diabetes and is likely to
become an increasing clinical problem. Unfortunately, the
mechanistic basis of this enhanced sensitivity is incompletely
understood. In this review, we describe evidence for the
involvement of candidate mechanosensitive channels such as
Piezo2 and their role in allodynia, as well as the peripheral and
central nervous system mechanisms that have also been im-
plicated in this form of pain. Specific treatments that reverse
mechanical allodynia could be very useful if the cell and
molecular basis of the condition could be determined. There
are many potential mechanisms underlying this condition
ranging from alterations in mechanotransduction and sensory
neurons excitability to the actions of inflammatory mediators
and wiring changes in the CNS. As with other pain conditions,
it is likely that the range of redundant mechanisms that cause
allodynia will make therapeutic intervention problematic.
Introduction
Pain is a vast and increasing problem, affecting around a fifth
of the population. This problem is exacerbated by ageing
populations with conditions such as diabetes and osteoarthri-
tis, who suffer an even higher incidence of ongoing pain.
Strikingly, the drug industry has made little progress in devel-
oping new classes of analgesics, and many companies have
given up the struggle, making the development of useful
treatments even less likely. Mechanical allodynia is a condi-
tion where pain caused by innocuous stimuli like the touch of
clothing may be debilitating, but the condition is little
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addressed in terms of drug development because other pain
syndromes are more common. The phenotypic distinction
between allodynia and hyperalgesia is shown schematically
in Fig. 1.
There have been some recent advances in understanding
the cell and molecular basis of mechanical hyperalgesia. For
example, a critical role for NGF in damaged tissues has been
linked to mechanically evoked pain in osteoarthritis, and this
pain can be reversed in man by the application of neutralising
anti-NGF monoclonal antibodies [21]. At the same time, the
expression of mechanosensitive channels on the surface of
cultured sensory neurons has been shown to be upregulated by
NGF through a transcriptional mechanism, linking sensory
neuron mechanotransducing channels functionally with en-
hanced mechanical pain [5]. This observation has led to
attempts to characterise intrinsically mechanosensitive ion
channels on sensory neurons and examine their role in
mechanotransduction, hyperalgesia and allodynia.
Peripheral mechanisms linked to mechanical allodynia
Mechanotransducing channels expressed by sensory neurons
in culture have been characterised electrophysiologically
using a technique developed by Jon Levine [26].
Mechanosensitive sensory neurons can be divided into sub-
populations according to the mechanically activated current
they generate in response to membrane distension. Rapidly
adapting neurons involved in touch and proprioception are
known to display a low threshold current with fast inactivation
kinetics, consistent with their tonic response to mechanical
stimuli. Mechano-nociceptors in turn show a mixed repertoire
of rapidly, intermediately and slowly adapting currents with
higher activation thresholds, accordingly to the high intensity
of the stimuli to be detected [6]. It is still unknownwhether the
rapidly adapting currents found in nociceptors involve the
same channel(s) as the rapidly adapting current present in
low threshold mechanoreceptors. Evidence of a role for the
rapidly adapting channels Piezo2 and TRPC3/C6 in non-
noxious mechanotransduction by touch sensitive cells, as well
as in light touch sensitivity in vivo, has been obtained [10, 34].
When considering mechano-nociception, the slowly
adapting current found in sensory neurons is of particular
interest. Its slow inactivation kinetics is coherent with the
phasic (slowly adapting) afferent response coded by
mechano-nociceptors.More direct evidence of its contribution
to mechano-nociception has also been established. The
conotoxin NMB-1, shown to be a specific blocker of the
slowly adapting current in sensory neurons of the dorsal root
ganglia, increases mechanical pain thresholds without affect-
ing light touch sensitivity in vivo [8]. Exposure to botulinum
toxin has also been shown to chronically, but reversibly,
impair mechano-nociception in humans. In parallel, the num-
ber of sensory neurons expressing a slowly adapting, mechan-
ically activated, current is decreased in mice in vitro when
these neurons are cultured and exposed to botulinum toxin
[30]. The molecular identity of the channel or protein complex
responsible for the slowly adapting current remains unknown.
The TRPA1 channel has been found necessary for the exis-
tence of such a current in a subset of peptidergic sensory
neurons [40] and TRPA1 blockade reduces the firing of sen-
sory fibres in response to noxious mechanical stimuli [17]. In
vivo, Trpa1−/−mice were also shown to have a higher mechan-
ical pain threshold when analysed in the von Frey test [20, 32].
These are convincing pieces of evidence for a relatively direct
role of TRPA1 in the transduction of noxious mechanical
stimuli. However, TRPA1 fails to generate mechano-gated
currents when expressed in a heterologous system, showing
that it is not the mechanotransducer itself or that one or more
accessory proteins are required for TRPA1 to be opened by
membrane stretch [35, 40]. As TRPA1 is also expressed in
keratinocytes that are in close contact with nerve terminals in
the skin, an indirect contribution of TRPA1 to noxious
mechanotransduction cannot be excluded.
Furthermore, stretch-activated channels have to be consid-
ered as part of the wider transduction machinery involved in
specific tuning of cell excitability. For example, the Kv1.1
potassium channel, whose voltage-gated activation has recent-
ly been shown to be facilitated by membrane stretch [13], has
current kinetics that allows it to counter the depolarization
induced by the activation of the slowly-activating, but not the
rapidly-activating, mechano-gated channels present in
nociceptors. As a consequence, Kv1.1 blocking increases
mechanically induced depolarization in nociceptors, as well
as their firing threshold in response to mechanical stimuli, and
Kv1.1 knockout in mice are found to be hypersensitive to
Fig. 1 Sensitization to pain. This graphical representation of the shift in
pain thresholds during a pain state shows both enhanced response to
noxious, normally painful, stimuli (hyperalgesia) and pain triggered by
non-noxious stimuli (allodynia) like the gentle brush of the skin.
These two painful states do not always coexist, and it is increas-
ingly apparent that they are driven by distinct mechanisms in different
sets of sensory neurons
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mechanical stimuli in vivo. Other potassium channels like
TREK-1 and TRAAK, from the K2P family, have been shown
to be important for mechanical pain [2, 29]. However, they are
not specific for this modality and are rather involved in setting
the overall level of nociceptor excitability, whatever their
function may be.
Targeting the channel responsible for the slowly adapting
current, characteristic of noxious mechanotransduction, could
perhaps contribute to reducing pain in people suffering from
mechanical pain hypersensitivity, but rather than inhibiting
noxious mechanosensation, which could eventually lead to
new injuries or to the worsening of the original problem, for
example by aggravating a joint condition, we should aim for
the re-establishment of normal pain sensitivity. This is very
well illustrated by the effect of the anti-NGF treatment
Tanezumab in osteoarthritic patients [21]. NGF is known to
promote the over-expression of mechanosensitive channels
underlying rapidly as well as slowly adapting currents, and
PKC activation by inflammatory factors such as bradykinin
addresses the newly produced channels into the membrane
[5]. Neutralising NGF with Tanezumab has proven successful
in reducing joint pain, however, the induced mechanical an-
algesia has also been linked in a small number of cases with
rebound inflammation and joint failure in some of the people
treated with anti-NGF monoclonal antibody [44].
Details about the mechanisms leading to mechanical
allodynia, including what are the final effectors, and which
neuronal subtypes are involved, provide a complex picture.
The depletion of Nav1.8-positive sensory neurons in mice by
crossing animals carrying a floxed-stop upstream of the diph-
theria toxin A gene with Nav1.8-Cre mice reverses Freund’s
complete adjuvant-induced mechanical hyperalgesia [1].
However, genetic ablation of Nav1.8-positive neurons was
ineffective in reducing neuropathic mechanical allodynia in-
duced by spinal nerve transection. This shows that different
mechanisms, involving different populations of sensory neu-
rons, can cause mechanical hypersensitivity. We made a sim-
ilar observation on allodynia associated with neuropathic pain
using two models of traumatic neuropathic pain, induced by
spinal nerve transection and chronic constriction of the sciatic
nerve. In the first case, Nav1.7 conditional knock-out in the
whole dorsal root ganglion was sufficient to alleviate mechan-
ical allodynia, but the Nav1.7 knock-out had to be extended to
sympathetic neurons to abolish allodynia in a sciatic chronic
constriction injury [27]. The interplay between the sympathet-
ic nervous system and sensory neurons seems to be an impor-
tant factor in many types of neuropathic pain. However, there
are examples of mechanical allodynia (e.g. bone cancer pain)
that occur in the absence of Nav1.8-positive nociceptors, or
sodium channel Nav1.7 (considered essential for human pain)
whose mechanisms are completely obscure [27].
Much effort has been put into elucidating the specific
signalling cascades involved in the sensitization of sensory
neurons by immune mediators, consequently leading to the
development of hyperalgesia. Increasing evidence suggests
that sensitization of both transduction and neurotransmission
in nociceptors is a major cause of inflammatory hyperalgesia
[16, 45]. For example, inflammatory mediators have profound
effects on the heat transducer TRPV1 and voltage-gated sodi-
um channels present in sensory neurons. However, evidence
for the regulation of mechanical transduction in allodynic
states is just starting to emerge. The known pathways involved
are summarised in Fig. 2. The first intracellular messenger
associated with sensory neuron sensitization was cAMP.
Intradermal injections of cAMP analogues induce profound
mechanical hyperalgesia (reduced response thresholds to nox-
ious mechanical stimuli measured with the Randall-Selitto
test) but also increased responses to innocuous mechanical
stimuli (as measured with von Frey hairs), that is characteristic
of allodynia [36]. cAMP signalling has been primarily impli-
cated in the development of pain hypersensitivity in an in-
flammatory state as many inflammatory mediators signal
through G protein-coupled receptors that are coupled with G
proteins that activate (Gs) adenylate cyclase, whilst other
inflammatory mediators may cause an increase in intracellular
calcium that activates calcium-sensitive adenylate cyclases.
Pharmacological and genetic evidences also suggest a role
for cAMP in the development of mechanical allodynia in
rodent models of neuropathic pain [18, 22, 23]. For example,
the development of mechanical allodynia is severely impaired
in models of neuropathic pain in mice deficient for adenylate
cyclase 5 [18]. Several groups have used pharmacological and
genetic tools to identify whether the downstream cAMP sen-
sor PKA plays a role in mechanical allodynia in neuropathic
pain conditions. However, these studies did not show any
evidence for PKA involvement in such a condition [24, 46].
Yet strong evidence exists for a role of PKA in the develop-
ment of inflammatory mechanical hyperalgesia and enhanced
neuronal excitability has been linked to PKA mediated phos-
phorylation of sodium channels [16].
Although increases in intracellular cAMP have been con-
sidered to be equivalent to the activation of the cAMP sensor
protein kinase A (PKA), in 2001, the Bos group identified a
separate pathway activated by cAMP, the family of exchange
factors activated by cAMP (Epac). Activation of Epac leads to
subsequent activation of a small G protein: Rap1, that is
upstream of various effector proteins, including adaptor pro-
teins that affect the cytoskeleton, regulators of G proteins of
the Rho family, phospholipases and protein kinases [14]. In
non-peptidergic isolectin B4 positive sensory neurons, Epac
signalling mediates cAMP-to-PKCε signalling, leading to
inflammatory hyperalgesia [15]. We recently showed that
injection of a specific Epac activator also induces hypersensi-
tivity to innocuous mechanical stimuli that is independent of
Nav1.8 nociceptors [10], normally associated with the
development of inflammatory hyperalgesia [1]. In contrast,
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activation of the PKA signalling cascade by intradermal in-
jections of a specific PKA agonist also results in reduced
mechanical thresholds, yet this mechanical hypersensitivity
was completely dependent on Nav1.8 neurons. In Epac1
knockout mice, nerve damage induced mechanical allodynia
is impaired, indicating an important role for this cAMP sensor
in the development of mechanical allodynia. Interestingly, in
chronic inflammatory pain, knockdown of Epac1 during al-
ready developed persistent mechanical hypersensitivity also
reduces the symptom, whilst acute transient inflammatory
hyperalgesia is unaffected in Epac1 knockout mice [42].
In vitro activation of the Epac signalling cascade sensitises
large diameter neurons that express rapidly adapting mechan-
ically activated currents [10] and that have been linked to
touch sensitivity [43]. The Piezo protein family that includes
Piezo1 and Piezo2 has been shown to mediate some of the
rapidly adapting currents in sensory neurons [5]. In a
heterologous expression system, activation of the cAMP sen-
sor Epac1 enhances Piezo2 currents, whilst specific activation
of PKA using 6-Bnz-cAMP, activation of PKC using PMA or
activation of Epac2 by 8-pCPT does not affect Piezo2 sensi-
tivity [10]. Thus, cAMP-to-Epac1 signalling would specifi-
cally sensitises Piezo2 current. Inflammatory mediators are
also capable of sensitising Piezo2 sensitivity. The algogenic
peptide bradykinin produced during inflammation enhances
Piezo2 current in a heterologous expression system [9]. This
effect is blocked by the concomitant use of PKA and PKC
inhibitors, and in parallel, the use of either a cAMP analogue
or a PKC activator were shown to enhance Piezo2 current. In
vivo, we found that sensitization of Piezo2 by Epac1 plays a
role in the development of mechanical allodynia. Partial anti-
sense knockdown of Piezo2 in the dorsal root ganglia of mice
attenuates mechanical allodynia in two different model of
nerve injury. In addition, mechanical allodynia induced by
Fig. 2 Signalling pathways for the sensitization of mechanosensitive
sensory neurons. Different but interconnected pathways have been shown
to contribute to the sensitization of mechanosensitive neurons, leading to
allodynia. PKA and PKC are known to be important for neuronal excit-
ability, notably through voltage-gated sodium channel modulation [12,
39], but more recently, they were also found to have an effect on
mechanotransduction directly. Indeed, the low threshold mechano-gated
channel Piezo2 has been shown to be positively modulated by PKC, PKA
[9] and by the cAMP sensor EPAC1 [10]. EPAC1, but not EPAC2,
enhances Piezo2 current by activating the G protein Rap1 when activated
by cAMP. cAMP increases can be induced directly by the activation of
GPCR coupled to Gs proteins (PGE2 receptor EP2, histamine H2 receptor,
CALCRL receptor for CGRP, serotonin receptor 5-HT4…) or indirectly
via a calcium increase, induced either by an ion channel (TRPs, ASICs,
P2Xs…) or by IP3-mediated calcium increase following either activation
of a PLC coupled tyrosine kinase receptor (e.g. neurotrophin receptors) or
activation of a GPCR coupled to Gq proteins (PGE2 receptor EP1,
histamine receptor H1, serotonin receptor 5-HT2…). PLC activation will
also result in DAG-mediated activation of PKC, which has also been
shown to positively regulate Piezo2 channels [9]. However, PKA and
PKC activation were found to have no effect on the human Piezo2
channel [10]. Therefore, further work is needed to clarify Piezo2 modu-
lation by these signalling pathways. TRPC3 and TRPC6 channels were
also found to be involved together in the generation of a low threshold
mechanically activated current and to be essential for normal touch
perception [34]. It is not known whether these channels are subject to
the same positive regulation as Piezo2. Mechano-gated channels produc-
ing rapidly, intermediately and slowly adapting currents, yet to be iden-
tified, are also positively regulated by NGF and PKC [5]. In sensory
neuron cultures, TrkA activation by NGF leads to transcription of new
channels, and activated PKC promotes the insertion of the channels into
the membrane to increase peak currents [2]
136 Pflugers Arch - Eur J Physiol (2015) 467:133–139
intraplantar injection of a specific Epac agonist is attenuated
by Piezo2 knockdown [10]. These findings highlight that the
tuning of Piezo2 current by the cAMP-Epac1 signalling cas-
cade plays an important role in the dysregulation of
mechanotransduction leading to mechanical allodynia.
An important question that arises is whether in chronic
neuropathic pain conditions, continuous driving forces such
as elevated levels of cAMP sustain the sensitization of
mechanotransduction leading to allodynia. Recently, a specif-
ic Epac antagonist has been developed and could prove useful
in testing whether it can reverse chronic mechanical allodynia
[3].
Central mechanisms implicated in the development
of mechanical allodynia
A variety of central mechanisms have been implicated in the
establishment of allodynia, including phenotypic changes in
peripheral and central neurons as well as an important role for
cells of the immune system. Perhaps, the most surprising
aspect of nerve damage-related allodynia is the critical role
of activated microglia within the central nervous system in this
phenomenon, at least in rodent models of these conditions [4].
Sensory neurons are known to play an important role in
wound healing through the release of immunoregulatory mol-
ecules and mitogens that catalyse the response to injury asso-
ciated with damaged nerve. One way of thinking about the
role of microglia in neuropathic pain is to imagine that the
same signals are aberrantly released from seriously damaged
nerves both centrally and peripherally, and the recruitment and
activation of microglia centrally may be an unfortunate spin-
off from the normal neuro-immune interplay involved in
wound healing in the periphery. Activation of the ionotropic
ATP receptor P2X4 expressed by microglia leads to the re-
lease of mediators such as brain-derived neurotrophic factor
(BDNF) that can alter chloride transport in the terminals of
sensory neurons and dorsal horn neurons, leading to altered
patterns of excitability that have been linked to allodynia [4,
38]. Recent evidence suggests that diabetic neuropathy lead-
ing to allodynia also involves microglia in animal models
[41].
A surprisingly large number of insults seems to be able to
induce mechanical allodynia, including peripheral activation
of channels that are known to be mechanically insensitive,
such as the heat-sensor TRPV1 [31]. Intriguingly, many pep-
tide mediators associated with small-diameter sensory neu-
rons [calcitonin gene-related peptide (CGRP), substance P,
BDNF], as well as chemokines [25] have been shown to
evoke allodynia when applied intrathecally. Thus, a major
afferent barrage from peptidergic nociceptive neurons may
sensitise dorsal horn neurons that are normally wired for
mechanosensitive input through the possible extra-synaptic
actions of these mediators. Specific antagonists of TRPV1
can block mechanical allodynia, suggesting that presynaptic
TRPV1 activation is an important element in the release of
pro-allodynic mediators. Thus, afferent barrage leading to
second-order neural depolarization may cause the release of
arachidonic acid metabolites such as 9-HODE that amplify the
release of neuromodulators in the dorsal horn [31]. In this way,
despite the known mechano-insensitivity of peripheral
TRPV1, presynaptic amplification of nociceptive inputs
through this receptor contributes to mechanical allodynia.
In the dorsal horn of the spinal cord, the increased periph-
eral input from sensitised primary afferent fibres also results in
TRPV1 activation in GABAergic interneurons. TRPV1 open-
ing increases the intracellular calcium concentration which, if
prolonged, will result in long-term depression of these inhib-
itory interneurons. The GABAergic inhibition exerted on the
spinothalamic tract will be released, resulting in enhanced
nociceptive inputs to the thalamus [19]. Long-term potentia-
tion of spinal nociceptive neurons and long term depression of
inhibitory interneurons together may contribute to setting a
greater ongoing activity of dorsal horn neurons and a to the
increase of the response intensity to noxious mechanical stim-
uli. Another consequence of glycinergic inhibition removal is
the development of a crosstalk between separate spinal lami-
nae that may be responsible for the rerouting of sensory inputs
within the spinal cord. It has been shown, for example, that in
response to the pharmacological removal of gycinergic inhi-
bition in the trigeminal ganglion, a local dormant circuit
involving PKCγ interneurons is activated, resulting in the
gating of tactile inputs to superficial nociceptive specific
neurons, turning touch into pain [28]. Nociceptive specific
neurons of the spinal cord can furthermore be sensitised
through the phenomenon of wind-up (a type of LTP) through
the release of substance P by myelinated primary afferent
fibres [33]. There is also evidence that myelinated afferent
fibres also undergo phenotypic changes that may contribute to
the appearance and maintenance of mechanical allodynia in,
for example, the expression of potassium channels [37].
Conclusions and future prospects
Strategies for dealing with allodynia fall into four broad
categories. First, identifying and blocking the mediators that
sensitise mechanosensory neurons within the peripheral and
central nervous system has had some success. In particular, a
number of mediators released from activated microglia such
as BDNF, as well as various cytokines and NGF all play a role
in regulating mechanosensitivity and are potential targets.
Secondly, blocking the mechanotransducing channels them-
selves may be attractive when we finally have a complete list
of the molecules involved. As yet, only Piezo2 has been
shown to have a potential role in allodynia. Thirdly, attacking
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electrical excitability in the peripheral neurons that are impli-
cated in allodynia may be useful. A number of pharmacolog-
ical treatments have been described that diminish allodynia in
animal models through sodium channel block, including
conotoxin sodium channel-selective blockers that target
Nav1.7 and Nav1.8 and limits mechanical hyperalgesia and
allodynia [11]. Finally, dismantling the aberrant circuitry that
has been linked to allodynia is a potential, if exceptionally
complex approach to the problem. It is clear that allodynia
results from peripheral drive involving subsets of neurons that
are not classical nociceptors, and the sympathetic nervous
system plays an important role in some allodynic syndromes.
However, there is much basic information that is still lacking,
for example, the mechanistic relationship between cold and
mechanical allodynia. In particular, a genetic analysis of the
role of subsets of A-fibre associated sensory neurons in neu-
ropathic allodynia would be a useful first step in unravelling
the circuitry that is involved in the establishment of this
unpleasant condition.
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